Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 1.83% is 89% below its 5-year average of 17.15%, near the low end of its 5-year range (1.83%–22.39%).
As of the fiscal period ended Wednesday, December 31, 2025. 86.28% below its 12-month average of 13.34%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
1.83%
RETURN ON ASSETS (ROA) AVG TTM
13.34%
RETURN ON ASSETS (ROA) AVG 3Y
15.53%
RETURN ON ASSETS (ROA) AVG 5Y
17.15%
RETURN ON ASSETS (ROA) AVG 10Y
14.96%
RETURN ON ASSETS (ROA) AVG 15Y
15.65%
RETURN ON ASSETS (ROA) AVG 20Y
15.68%
CURRENT VS TTM AVG
-86.28%
CURRENT VS 3Y AVG
-88.22%
CURRENT VS 5Y AVG
-89.33%
CURRENT VS 10Y AVG
-87.77%
CURRENT VS 15Y AVG
-88.31%
CURRENT VS 20Y AVG
-88.33%
SECTOR MEDIAN · HEALTHCARE
4.97%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-63.18%
vs the sector median at left
Waters Corporation
Market Cap
$24.59B
Return on Assets (ROA)
1.83%
TTM Avg
13.34%
3Y Avg
15.53%
5Y Avg
17.15%
Market Cap
$24.23B
Return on Assets (ROA)
20.48%
TTM Avg
9.54%
3Y Avg
8.43%
5Y Avg
7.44%
Market Cap
$24.00B
Return on Assets (ROA)
13.86%
TTM Avg
12.54%
3Y Avg
14.20%
5Y Avg
14.86%
Market Cap
$25.35B
Return on Assets (ROA)
5.41%
TTM Avg
4.41%
3Y Avg
4.42%
5Y Avg
6.18%
Market Cap
$25.72B
Return on Assets (ROA)
6.27%
TTM Avg
5.75%
3Y Avg
6.24%
5Y Avg
8.30%
Market Cap
$22.91B
Return on Assets (ROA)
-6.03%
TTM Avg
-3.96%
3Y Avg
9.16%
5Y Avg
17.06%
Market Cap
$21.98B
Return on Assets (ROA)
19.17%
TTM Avg
16.59%
3Y Avg
14.73%
5Y Avg
13.22%
Market Cap
$21.75B
Return on Assets (ROA)
-28.75%
TTM Avg
-24.02%
3Y Avg
-10.32%
5Y Avg
-0.33%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Waters Corporation (WAT) | $24.59B | 1.83% | 13.34% | 15.53% | 17.15% |
| Incyte Corporation (INCY)vs › | $24.23B | 20.48% | 9.54% | 8.43% | 7.44% |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.00B | 13.86% | 12.54% | 14.20% | 14.86% |
| Labcorp Holdings Inc. (LH)vs › | $25.35B | 5.41% | 4.41% | 4.42% | 6.18% |
| Quest Diagnostics Incorporated (DGX)vs › | $25.72B | 6.27% | 5.75% | 6.24% | 8.30% |
| BioNTech SE (BNTX)vs › | $22.91B | -6.03% | -3.96% | 9.16% | 17.06% |
| STERIS plc (STE)vs › | $22.26B | 7.29% | 6.68% | 4.44% | 4.33% |
| United Therapeutics Corporation (UTHR)vs › | $21.98B | 19.17% | 16.59% | 14.73% | 13.22% |
| Moderna, Inc. (MRNA)vs › | $21.75B | -28.75% | -24.02% | -10.32% | -0.33% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $27.44B | 14.54% | -0.12% | -10.91% | -15.37% |
ROA
1.8%
ROE
2.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 12.66% |
| 2024-12-31 | 14.01% |
| 2023-12-31 | 13.88% |
| 2022-12-31 | 21.57% |
| 2021-12-31 | 22.39% |
| 2020-12-31 | 18.37% |
| 2019-12-31 | 23.16% |
| 2018-12-31 | 15.93% |
| 2017-12-31 | 0.38% |
| 2016-12-31 | 11.19% |
| 2015-12-31 | 11.01% |
| 2014-12-31 | 11.13% |
| 2013-12-31 | 12.59% |
| 2012-12-31 | 14.57% |
| 2011-12-31 | 15.90% |
| 2010-12-31 | 16.40% |
| 2009-12-31 | 16.95% |
| 2008-12-31 | 19.87% |
| 2007-12-31 | 14.25% |
| 2006-12-31 | 13.74% |
| 2005-12-31 | 14.13% |
| 2004-12-31 | 15.34% |
| 2003-12-31 | 15.11% |
| 2002-12-31 | 14.61% |
| 2001-12-31 | 12.91% |
| 2000-12-31 | 20.99% |
| 1999-12-31 | 20.93% |
| 1998-12-31 | 12.88% |
| 1997-12-31 | -1.50% |
| 1996-12-31 | -0.66% |
